Jill Andersen Sells 37,256 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 37,256 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32. Following the completion of the transaction, the insider owned 314,480 shares of the company’s stock, valued at approximately $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total transaction of $25,793.04.

Invivyd Stock Performance

Shares of IVVD opened at $0.96 on Thursday. The stock has a market cap of $282.82 million, a PE ratio of -2.91 and a beta of 0.71. Invivyd, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm’s 50-day simple moving average is $0.77 and its two-hundred day simple moving average is $1.23.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Equities research analysts predict that Invivyd, Inc. will post -0.52 EPS for the current year.

Trending Headlines about Invivyd

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Hedge Funds Weigh In On Invivyd

Hedge funds have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC purchased a new stake in Invivyd during the 1st quarter valued at $25,000. Courier Capital LLC purchased a new position in shares of Invivyd in the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd during the fourth quarter valued at $27,000. DRW Securities LLC bought a new position in shares of Invivyd during the fourth quarter valued at $27,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Invivyd during the fourth quarter valued at $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on IVVD shares. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.